IE840682L - Bis(piperazinyl or homopiperazinyl) alkanes - Google Patents

Bis(piperazinyl or homopiperazinyl) alkanes

Info

Publication number
IE840682L
IE840682L IE840682A IE68284A IE840682L IE 840682 L IE840682 L IE 840682L IE 840682 A IE840682 A IE 840682A IE 68284 A IE68284 A IE 68284A IE 840682 L IE840682 L IE 840682L
Authority
IE
Ireland
Prior art keywords
bis
piperazinyl
carbon atoms
hydrogen
propane
Prior art date
Application number
IE840682A
Other versions
IE57136B1 (en
Original Assignee
Boehringer Ingelheim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ltd filed Critical Boehringer Ingelheim Ltd
Publication of IE840682L publication Critical patent/IE840682L/en
Publication of IE57136B1 publication Critical patent/IE57136B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1. Bis-(piperazinyl- or homopiperazinyl) alkanes of the general formula I see diagramm : EP0122488,P21,F1 wherein R1 , R2 , R3 and R4 which may be identical to or different from each other, are each hydrogen, alkyl having 1 to 4 carbon atoms, hydroxyl, alkoxy having 1 to 4 carbon atoms, alkanoyloxy having up to 4 carbon atoms, halogen, trihalomethyl, di-C1-4 alkylamino, C1-4 alkoxycarbonyl, nitro, cyano or acyl having 1 to 3 carbon atoms ; R5 and R6 , which may be identical to or different from each other, are each hydrogen, methyl, hydroxyl, carboxyl, C1-4 alkoxycarbonyl, hydroxymethyl, phenyl or p-chlorophenyl, R7 and R8 are each hydrogen or methyl ; j and k are integers from 0 to 3, their sum being no more than 4 ; m and n are integers from 0 to 3, their sum being no more than 4 ; A is -CH2 - or -CH2 CH2 - ; or R5 and R7 together or R6 and R8 together are oxo, provided k or m is other than O ; or R5 and R7 together and R6 and R8 together are oxo, provided k or m are other than O ; R9 and R10 , which may be the same or different, represent hydrogen or from one to four methyl substituents on the carbon atoms of the piperazine ring (A = -CH2 -) ; R11 , R12 , R13 and R14 , which may be identical to or different from each other, are each hydrogen or methyl ; or R11 and R12 together and/or R13 and R14 together are oxo ; and X is alkylene of 1 to 2 carbon atoms, optionally hydroxy-substituted with the proviso that when A = -CH2 -, R1 to R14 are hydrogen and j, k, m and n are each zero, then X cannot be 1,2-ethylenediol, and physiologically acceptable acid addition salts thereof.

Description

This invention relates to novel bis(piperazinyl or liomopiperassinyl) alkane-.> and non-toxic acid addition salts 5 thereof, to methods o£ preparing these compounds and to «harma- ceutical compositions containing them . The above--mentioned compounds may be used as antiallergics and anti-inflainmatories. 10 Compounds of the formula 15 wherein n is 2, 6, 8, 9 or 10 are described by s. Chiavarelli, P. Mazzeo, F. Costa and A. H. Russo in Farmaco, Ed. Sci. 20, 229 (1965) as having a curare-like activity.
J. van Alpen in Rec. Trav. Chin. 55, 835 (1936) 20 discloses the synthesis of polyamines of the formulae without ascribing a biological activity to them. -2- In J. Org. Chem. 24, 764 (1959) C.B. Pollard, W.M. Lauter and M. 0. Nuessle describe the preparation o£ compounds of the formula wherein H is H, alkyl or halo. No biological properties are ascribed to them.
Belgian Patent No. 633,453 discloses compounds of the formula wherein R is halo or alkoxy having antimalarial, anthelmintic and amebicidal properties.
Finally,. H. J. Dorokhova, V. A. Cheraow, S. M. Hinakova, 0. Y. Tikhonova and A. N. Zamskaya, Khim.-Faxm. Zh., 10, 36 (1976), abstracted in C.A. 85, 78079, describe compounds of the formula wherein n is 2, 3, 6 or 10, as precursors of compounds of the formula VIII below.
In one aspect, the present Invention provides b1s(piperaz1nyl or > homopiperazlnyl) alkanes of formula I Rl (I) 10 wherein Rj, R2, R-j and R^ which may be Identical to or different from each other, are each hydrogen, alkyl having 1 to 4 carbon atoms, hydroxy!., alkoxy having 1 to 4 carbon atoms, alkanoyloxy having up to 4 carbon atoms, halogen, trihalomethyl, di-C^ alkylamlno, IS alkoxycarbonyl, nitro, cyano or acyl having 1 to 3 carbon atoms; Rg and Rg, which may be Identical to or different from each other, are each hydrogen, methyl, hydroxy1, carboxyl, alkoxycarbonyl, hydroxynethyl, phenyl or p-chlorophenyl; R7 and Rg are each hydrogen or methyl; 20 j and k are integers from 0 to 3, their sum being no more than 4; m and n are integers from 0 to 3, their sum being no more than 4; A is -CHg- or -CHgCHg-; or R^ and R^ together or Rg and Rg together are oxo, provided k or m is other than 0; or 25 Rg and Ry together and Rg and Rg together are oxo, provided k or m is other than 0; Rg and Rjg, which may be the same or different, represent hydrogen or from one to four methyl substituents on the carbon atoms of the piperazine ring (A - -CH2-); 30 RirR12' r13 and r14' wh1ch "ay be identical to or different from each other, are each hydrogen or methyl; or Rjj and R^ together and/or R^ and together are oxo; and X is alkylene of 1 to 2 carbon atoms, optionally 35 hydroxy-substituted with the proviso that when A - -CHg-. Rj to R14 are hydrogen and j, k, m and n are each zero, then X cannot be 1,2-ethylenedlol, and physiologically acceptable acid addition, salts thereof. -4- Preferred compounds of formula I include those of formula II Especially preferred compounds of formula I include compounds of formula III 20 __ . ?11 ?15 ?13 C-CH—»(jl.-lCH2)b^-Cl R._ Rw 12 R14 (Itr) 25 wherein and R^ are H, or together are oxo; R^g is H or OH; Rjj and are H, or together are oxo; 30 and a and b are each 1, 2, 3 or 4 and physiologically acceptable acid addition salts thereof. -5- but other salts nay be useful in the preparation of the free base or of pharmacologically acceptable salts and so are included within the scope of the present invention. Examples of non-toxic, pharma-5 cologically acceptable acid addition salts include those formed with a hydrohalic acid, especially hydrochloric or hydrobromic acid, nitric acid, i sulfuric acid, o-phosphoric acid, citric acid, maleic acid, fumaric acid, propionic acid, butyric 10 acid, acetic acid, succinic acid, nethanesulfonic * acid, benzenesulfonic acid, p-toluenesulfonic acid, or the like. 15 The process for the preparation of the compound comprises at least one of the following stepst PROCESS A 20 — Reacting a compound of formula IV 25 fn ^13 Y—C—X—C— (IV) ^12 r14 30 (wherein Rp , Rj2 , R|3 Rj4 and X are as defined above and Y and z are groups reactive with amine groups to form a carbon-nitrogen bond, e.g. chloro, brono, iodo, activated ester, hydroxyl, sulfuric 35 ester, sulfonic ester or the like) with a compound of formula V -6- R h R7 2>vtK I A~\ r .^(C^lj-j-fCHjIk-il »H 5 R- 5 *9 » wherein R^, R2, Rg, Ry» Rg, j, k and A are as defined above ; » 10 PROCESS B reacting a compound of formula VI 15 f7 ^ r11 ?3 (CH2) j-C- (CH2) k-N^JN-c—X—C-y (VI) ^ Rg R1Z BI4 20 wherein R^, R2r ^Rg, Rjji ^ ' ^3 * ^14 X, j, k and A are as defined above and Y ts a reactive qroun with /a compound of formula VII 25 30 R ft ^6- ^ Rg I3 A~\ (CH2) C—(CH2) —*.MB (VII) R6 X *10 wherein R^, R^, R^, Rio' R| and A are as defined above ; 35 PROCESS C to prepare compounds of formula I, which is symmetrical about central group X, -7- reacting a compound of formula VIII r-ii r13 ^-\ r1 r a~\ hn h—c—x—- c—n nh (viii) w I - I w r b1z ^4 r. 9 • no 10 wherein Rg , R|q , R-jj , ^12'' ^13 ' ^14 ^ and A are as defined above with a compound of formula IX 15 R, R, ^ . 4V , (IX) 2\A I' <5^- (ch2) (ch2) k—* Rc 5 20 3 wherein R^, r2, Rg, Ry, ?, j, and k are as defined above ; 25 PROCESS 0 to prepare compounds of formula I wherein X is a carbinol moiety reacting a compound of formula X -8- I I I *12 H R14 10 wherein , r12 » R13.» R^ are as defined above, anrf y has the sare meaning as in formula IV with a compound of formula VII (as defined above)j and Optionally 15 /converting a compound of formula I nroduced by one of the processes a) toD) into a physiologically acceptable salt thereof in a manner known per se.
The condensation reactions described in processes (A) to (D) may be performed in the presence or 20 absence of a solvent. Aqueous or organic inert solvents, depending on the nature of the reactants, may be employed. Such solvents include dimethylsulfoxide, dimethylformamide, dioxane, ethoxyethanol and alkanols containing up to five carbon atoms, with or without 25 the addition of water. Aromatic hydrocarbons may also be employed. It is preferred, but not essential, to perform the reaction in the presence of an acid-binding agent such as triethylamine, and an alkali metal carbonate or an alkali metal hydroxide. 30 The reaction temperature depends on the starting compounds and on the solvent, which is used for the reaction and lies between ambient temperature and the reflux temperature of the reaction mixture. The reaction time is temperature-dependent and 35 may be several minutes to many hours.
A compound of formula I in which Rg and/or Rg are hydroxyl is desired, a compound of formula I wherein Rg and R j and/or Rg and Rg -9- together are oxo may be hydrogenated with conventional hydrogonating agents, such as sodium borohydride, in a manner known per se to obtain the desired hydroxy-substituted compound. j The starting compounds for process steps (A) to (D) are known compounds or may be prepared by known methods. 10 Thus, compounds of formula V are described in British Patent No. 480,358 and J. Am. Chem.Soc., 66, 263 (1944).
The synthesis of compounds of the formula VI is known from numerous publications, such as 15 Helv.Chim.Acta 41, 1072 (1958) or Monatshefte 87, 701 (1956).
Compounds of the formula VIII are disclosed in British Patent No. 480,358 and Khim.-Parm.Zh. 10, 36 (1976), abstracted in C.A. 85, 78079. 20 The following compounds are examples of end products of the formula I and their salts which may be prepared by the methods described above: -10- 1,3-Bis~{ 4-(4-hydroxybenzyl)-1-piperazinylJ propane tatra- hydrochloride, 1,3-Bis-{4-(4-chlorobenzyl)-1-piperazinyl)propane tetra-hydrochloride, 1.3-Bis-( 4- (4-chlorobenzyl) -1-piperazinyl]-2-hydroxy-propane, 1.4-Bifr{ 4-(4-chlorobenzyl)-1-piperazinyl ]-butane hemihydrate, 1,3-Bis-(4-benzy1-l-piperaziny1^propane tetrahydrochloride, 1,3-BiH4- (4-f luorobenzyl) -1-piperazinyl }propane- tatra- hydrochloride, 1,3-Bis-l 4- (4-chlorobenzyl) -l-piperazinyl]-l-oxopropane trihydrochloride, 1,3-Bis-{4- (4-chlorobenzyl) -1-piperazinyl]-1-methylpropane tetrahydrochloride hemihydrate, 1,3-Bis-{4-(4-chlorobenzhydryl)-l-piperazinyl^propane dihydrochloride dihydrate, 1-[4-(4-chlorobenzyl)-l-piperazinyl]-3-[4-(2-ethoxycarbonyl-2-phenylethyl)-1-piperazinylKpropane tetrahydrochloride monohydrate, 1-[4-(4-chlorobenzyl)-1-piperazinyl]-3-(4-phenacyl-l- piperazinylVpropane tetrahydrochloride-monohydrate, l,3-Bi»(4-phenacyl-l-piperazinyl>propane tetrahydrochloride -monohydrate, 1,3-Bis-[4-(2-phenyl-2-hydroxyethyl)-1-piperazinyl 1 - propane tetrahydrochloride, 1,3-Bis^4-phenethyl-l-piperazinyl>propane dihydrochloride dihydrate, 1-14-(4-chlorobenzyl)-1-piperazinyl1-3-f 4-(2-hydroxy-2- phenylethy1)-1-piperazinyl(propane-tetrahydrochloride, 1,3-Bis44-(4-chlorobenzyl)-1-piperazinyll-l,3-dioxopropane dihydrochloride monohydrate, -n- 1,3-Bis44-(4-chlorophenethyl)-l-plperazinyl]propaiie, 1,3-Bis-{4-(1-phejiylethyl)-1-piperazinylJpropane tetrahydrochloride, 1,3-Bis44-(4-chlorobenzyl)-2,5-clitnethyl-l-piperazinyl]- propane tetrahydrochloride dihydrate, 1,3-Bis-[4- (4-methoxybenzyl)-l-piperazinyl)£ropane, 1,3-Bis-[4-(3,4-dichlorobenzyl)-1-piperazinyl]propane tetrahydrochloride, 1,3-Bis{4-(2-chlorobenzyl)-1-piperasinylVpropane tetrahydrochloride, 1,3-Bis-[4- (4-aethylbenzyl) -1-piperaziay lVpropaxie tetrahydrochloride, 1,3-Bis-{4- (3-chlorobenzyl)-l-piperazinyHpropane dihydrochloride monohydrate, 1,3-Bis-[4- (3-{4-chlorophenyl}propyl) -1-piperazixiyll-pxapane tetrahydrochloride monohydrate, 1,3-Bis-t4-(4-butoxybenzy1)-1-piperaziny\Vpropane, 1,3-Bi«-£4-(4-aeetoxybenzyl)-1-piperazinyiypropane tetrahydrochloride, 1,3-Bi»{4- (4-bro®obenzyl) -l-piperazinyl}?ropane, 1,3-Bis-{4-(4-chloro-3-trifluoromethylbenzyl)-l-piperazinyl5- propane tetrahydrochloride 1,3-Bis-t{4- (4-chlorobenzyl) -2,3,5,6--tatramethyl}-l- piperaz iny 1 ]propane, 1,3-Bia-t4-{4-(4-chlorophenylbutyl)}-l-piperazinyl^propane, 1-[4-(4-chlorobenzyl)-1-piperazinyl]-3-14-(2-carboxy-2- phenylethyl)-1-piperazinyl^propane tetrahydrochloride. 1» 3-8is-{4-(4-chlorobenzyl)-l-homopiperazinylIpropane . tetrahydrochloride, 1,3-Bis-(4-(3-{4-chloropheny1}-propyl)-l-homopiperazinyl]-propane tetrahydrochloride, and 1/3-Bis{ 4-{4-chlorbbenzylJ-1-homopiperaz iny1]-1,3-diosco-propane. -13- The following examples illustrate the present invention and will enable others skilled in the art to understand it more completely. It should be understood, however, that the invention is not limited solely to the particular examples given below.
Example 1 1,3-3is-(4-<4-chlorobenzyl)—1-plperazinyltpropane tetrahydrochloride A mixture of 10.5 g of 1-(4-chlorobenzyl)-piperazine, 9.5 g of 1-bromo-3-chlorppropane, and 100 ml of reagent ethanol was refluxed for 17 hours. The solvent was then removed by rotary evaporation. The resulting oil was mixed with 200 ml of 1M dibasic potassium phosphate. Solid tribasic sodium phosphate was slowly added until the pS rose above 9. This mixture was extracted 5 times with 50 ml portions of ether. The ether was evaporated, and the residue was acidified with 100 ml of 2M phosphoric acid and filtered. The aqueous filtrate was then made basic with 2N sodium hydroxide, again extracted into ether (250 ml) and dried over magnesium sulfate. The product was precipitated with gaseous hydrogen chloride and recrystalllzed from reagent ethanol/water to give 5.8 g (399 of theory) of -14- 1,3-bis[4-(4-chlorobenzyl)-1-piperazi ny1]propane tetrahydrochloride as a white crystalline solid (m.p. 261-274°C, with decomp.)• Example 2 1,3-Bis-t 4-(4-chlorobenzyl)-1-piperazinyl 1-2-hydroxypropane .
A mixture of 4.4 g of epichlorohydrin, 20.1 g of 1-(4-chlorobenzyl)piperazine, 6.0 g of triethylamine and 50 g of reagent ethanol was refluxed for'3 days. The solvent was removed from the reaction, mixture by rotary evaporation, and the residue was then made basic with 2N sodium hydroxide and extracted with ether (5 x 100 al). The ether extract was dried over magnesium sulfate and evaporated, leaving an oil which solidified on standing. Kecrystallization from heptane resulted in the isolation of IS.6 g (82% of theory) of 1,3-bis[4-(4-chlorobenzyl)-1-piperazinyl]-2-hydroxy-propane as a colorless crystalline solid (m.p. 85-86.5°C).
Example 3 1,4-Bis-[4-(4-chlorobenzyl)-l-plperazinyllfcutane hemihydrate A mixture of 2.2 g of 1,4-dibromobutane, 4.2 g of l-(4-chlorobenzyl)piperazine, 2.8 g of anhydrous potassium carbonate and 20 ml of reagent ethanol was refluxed for 18 hours. The solvent was evaporated under reduced pressure, and the residual oil was heated for 16 hours at 160*C. The product was dissolved in 50 ml of hot water and extracted with ether (3 x 80 ml). The ether extract was concentrated to an oil which was chromatographed on a silica column, the eluant being CH 2C12/CH^OH/amraonium hydroxide (45:5:1). The resulting brown solid was dissolved in acetone and precipitated with water to give 0.8 g (35% of theory.) of 1,4-bis[4-(4-chlorobenzyl)—1-piperazinyl] butane hemihydrate as a white crystalline solid (m.p. 101—103°C).
Example 4 1,3-Bis^4-benzyl-l-piperazinyl)4>ropane tetrahydrochloride A mixture of 7.0 g of 1—benzylpiperazine, 3.2 g of l-brooo-3-chloropxopane, 4.0 g of triethylamine and 100 ml of reagent ethanol was refluxed for 2 Vs hours. The reaction mixture was then poured into 1 liter of ether, and the precipitated triethylamine salt was filtered off. The filtrate was evaporated to leave a yellow oil, which was dissolved in 100 ml of heptane and filtered. The solvent was removed by rotary evaporation, and the residue was re-dissolved in ISO ml of ether. Addition of excess anhydrous hydrogen chloride precipitated 8.8 g (82% of theory) of 1,3-bis(4-benzyl-1-piperazinyl)propane tetrahydrochloride as a white crystalline solid (m.p. 250-265*C).
Example 5 1,3-Bls44-(4-fluorobenzyl)-l-piperazinylH>ropane tetrahydrochloride (a) A solution of 29 g of p-fluorobenzyl chloride in 50 g of reagent ethanol was added dropwise tc a stirred solution of 34.5 g of piperazine in 150 g of reagent ethanol. A cold water bath was used to maintain the -16- reaction temperature at 20°C during the addition. The reaction mixture was stirred for an additional 1 Vi hours and then added to 2 liters of ether. Precipitated piperazine hydrochloride was filtered off. The filtrate was concentrated to an oil, which was chromatographed on a silica column, the eluant being a mixture of CH2Cl2/metbanol/a]mnoni\ia hydroxide in the ratio of 45:5:1. After concentration of appropriate fractions, 21.7 g of l-(4-fluorobenzyl)piperazine were isolated as a colorless liquid (56% of theory). (b) A mixture of 5.8 g of 1-(4-fluorobenzyl)piperazine, 3.2 g of l-brojao-3-chloropropane, 4.0 g of triethylamine and 50 ml of reagent ethanol was refluxed for 3 hours and then poured into 1 liter of ether. The precipitate was filtered off, and the filtrate was evaporated to an oil. This oil was dissolved in 100 ml of ether and precipitated with excess anhydrous hydrogen chloride. Recrystallization from ethanol/water gave 3.3 g (29% of theory) of l,3-bis[4-(4-flnorobenzyl)-1-piperazinyl]propane tetrahydrochloride as a white crystalline solid (m.p. 228-237°C, with deccmp.).
Example 6 1,3-Bjs-{4- (4-chloro-bensyl)-l-piperazinyl1-l-» oxo-prooane trlhydrocn loride A mixture of 2.0 g of l-(4—chlorobenzyl)piperazine, 1.0 g of triethylamine, 20 g of xylene and C.8 g of 3-bromopropionyl chloride was refluxed fcr 18 hours. The reaction mixture was filtered, and the filtrate was mixed with excess hydrogen chloride-saturated ether until the mixture tested acidic to litmus. The resulting precipitate was filtered off and recrystalllzed from ethanol/water to yield 1.2 g (45% of theory) of 1,3-bis[4-(4-chlorobenzyl)-1-piperaz iny1]-1-oxopropane trihydrochloride as a white crystalline solid (m.p. 222-250°C, with decomp.).
Example 7 1,3-Bis-t4-(4-chlorobenzyl)-1-piperazinyl-1-mathylpropane tetrahydrochloride hemihydrate A mixture of 7.3 g of 1-(4-chlorobenzyI)piperazine, 2.8 g of 1,3-dibraaiobutane, 11.0 g at triethylamine and 50 ml of reagent ethanol was refluxed for 48 hours. The solvent was removed by rotary evaporation. The residue was mixed with 100 ml of toluene and then refluxed for 24 hours. The mixture was then poured into 1 liter of ether and filtered. The filtrate was evaporated to an oil, which was chromatographed on silica with CH^Clj/CH^OB/anmionium hydroxide-(45:5:1) as the eluant. The resulting oil was dissolved in 100 ml of ether and precipitated with excess anhydrous hydrogen chloride. This product was dissolved in water and precipitated by addition of acetone to give 1.2 g (11% of theory) of 1,3-bis14-(4-chlorobenzyl)-1-piperazinyll-l-methylpropane- tetrahydrochloride hemihydrate as a white crystalline product (m.p. 228-232°C).
Example 8 1,3-Bis-|4- (4-chlorobenzhydryl) -1-plperazinvl] -propane-dihydrochloride dihydrate A mixture of 7.4 g of N-(p-chlorobenzhydryl)-piperazine, 2.0 g of l-bromo-3-chloropropane, 1.6 g of triethylamine and 25 g of reagent ethanol were refluxed for 18 hours. The reaction mixture was made basic with 5N sodium hydroxide and extracted with methylene chloride (5 x 50 ml). The extract was dried over magnesium sulfate, and hydrogen chloride-saturated ether was added until the mixture tested acid to litmus. The precipitated crude 1,3-bis[4-(4-chlorobenzhydryl)—1-piperazinyl]propane dihydrochloride dihydrate (2.5 g, 27% of theory) was filtered off. Purification by dissolution in methylene chloride followed by precipitation by addition of ether resulted in a white crystalline product (m.p. 163-196°C, with decomp.).
Example 9 1-[4-(4-Chlorcbenzyl)—1-piperazinyl]-3-[4-(2-ethoxycarbonyl-2-phenylethyl)—1-piperazinyl1-propane tetrahydrochloride monohydrate (a) A mixture of 1.8 g of ethyl atropate and 0.9 g of piperazine was stirred in a round-bottom flask. When the exothermic reaction abated, the mixture was heated to 80"C and stirred for an additional 20 minutes. The reaction mixture was then allowed to stand overnight at ambient: temperature.. The resulting solid was chromatographed on a silica column using ether as the eluant, followed by CHjClj/CHjQH/ammonium hydroxide (45:5:1). The 1-(2-ethoxycarbonyl-2-phenylethyl)-piperazine product (0.75 g, 29% of theory) came off the column with the second eluant and was used in the following step without further purification. -19- (b) A mixture of 3.0 g of l-chloro-3-[4-(4-chlorobenzyl)~ 1-piperazinyl)propane, 3.5 g of triethylamine, 3.7 g of l-(2-ethoxycarbonyl-2-phenylethyl)piperazine and 50 ml of reagent ethanol was refluxed for 2 hours and was then poured into 1 liter of ether. The resulting mixture was filtered, and the filtrate was evaporated to an oil. This oil was purified by chromatography on a silica column, the eluant being CHjClj/CH^OH/ammonium hydroxide (45:5:1), to yield 3.0 g of an oil. This oil was dissolved in 150 ml of ether and precipitated with excess anhydrous hydrogen chloride to give 3.4 g of a solid. This product was re-chromatographed on silica using ether as the first eluant, then switching to the above methylene chloride mixture. The resulting product was converted into its hydrochloride as above, dissolved in water and precipitated by addition of acetone, to yield 1.1 g (15% of theory) of 1-[4-(4-chlorobenzyl)-1-piperazinyl)-3-I4-l2-ethoxycarbonyl-2-phenylethyl)-1-piperazinyl]propane tetrahydrochloride monohydrate as a white crystalline product (m.p. 198-2-l°C).
Example 10 1-I4-(4-Chlorobenzy1)-l-piperazinvl]-3-(4-phenacyl-1-piperazinyl)propane tetrahydrochloride monohydrate A mixture of 4.1 g of 1-phenacylpiperazine, 5.7 g of l-chloro-3-[4-(4-chlorobenzyl)-1-piperazinyl]propane, 2.6 g of triethylamine and 35 ml of reagent ethanol was refluxed for 5 hours. The solvent was removed by rotary evaporation, 150 ml of water were added, and the mixture was extracted with ether (3 x ISO ml). The ether solution -20- was evaporated to an oil, which was chromatographed on a silica column, the eluant being CHjClj/CH^OH/ammonium . hydroxide (45:5:1), to yield crude 1-[4-(4-chlorobenzyl)-1-piperazinyl]-3-(4-phenacyl-1-piperazinyl)propane (7.0 g, 50% of theory). This oil was dissolved in 200 ml of ether and precipitated with excess anhydrous hydrogen chloride. The precipitate was then dissolved in water and repreciplt-ated by addition of acetone to give 1-[4-(4-chlorobenzyl)-1-piperazinylJ-3-(4-phenacyl-l-piperazinyl)propane tetrahydrochloride monohydrate as a white crystalline product (m.p. 211-218-C).
Example 11 1-14-(4-Chlorobenzyl)—1-piperazinyl1-3-[4-(2-hydroxy-2-phenylethyl)—1-piperazinyl]propane tetrahydrochloride A solution of 3.0 g of 1-[4-chlorcbenzyl)-l-piperazinylJ-3-(4-phenacyl-l-piperazinyl)propane in 50 ml of reagent ethanol was mixed with 3.0 g of sodium boro-hydride. The mixture was stirred for 4 hours, and then the unreacted sodium borohydride was destroyed by the addition of 25 ml of acetone. The solvents were removed under vacuum, and 50 ml of water were added. The mixture was extracted with ether (3 x 2S0 ml). The extract was evaporated to an oil, which was chromatographed on a silica column, the eluant being CHjCIj/CHjOH/ammonium hydroxide (45:5:1). The fractions containing the desired product were combined and evaporated to an oil, which was dissolved in 100 ml of ether and precipitated by addition of excess anhydrous hydrogen chloride. The resulting solid was dissolved in water and precipitated with acetone to give 0.65 g (16% of theory) of 1-14-(4-chlorobenzyl)— 1-piperazinyl] -3-14-(2-hydroxy-2-phenylethyl)—1-piperaainvl]- -21- propane tetrahydrochloride as a white crystalline product (m.p. 240-248°C» with decomp.).
Example 12 1,3-BlM4-phenacy1-1-piperazinyl)propane tetrahydrochloride-monohydrate A mixture of 6.1 g of 1-phenacylpipara2ine, 2.4 g of l-bxamo-3-chloropropane, 3.1 g of triethylamine and 50 ml of reagent ethanol was refluxed for 3 hours and then evaporated to an oil. Water (250 ml) was added, and the mixture was extracted with ether (3 x 150 ml). After evaporation of the ether, the residual oil was chromatographed on silica, the eluant being CH 2C1j/CHjOH/amraoniuic hydroxide (45:5:1). The high purity fractions were combined and evaporated to an oil, which was dissolved in ISO ml of ether and precipitated with excess anhydrous hydrogen chloride. This solid was dissolved in water and precipitated by addition of acetone to give 1.3 g (14% of theory) of 1,3-bis-(4-phenacy1-1-piperazinyl)propane tetrahydrochloride monohydrate as a white crystalline product (m.p. 194-204aC).
Example 13 1,3-Bis-L4-(2-phenyl-2-hydroxyethyl)-l-piperaz inylfcpropane tetrahydrochloride . A solution of 2.5 g of 1,3-bis(4-phenacy1-1-piperazinyl)propane in 50 ml of reagent ethanol was mixed with 2.5 g of sodium borohydride and stirred for 4 hours. Residual sodium borohydride was destroyed by the addition of 25 ml of acetone, and then the solvents were removed by rotary evaporation. Water (50 ml) was added, and the mixture -22- was extracted with ether (3 x ISO ml). After evaporation of the ether, the product was chromatographed on silica, the eluant being CHjC^/Ci^OIl/ainmonium hydroxide (45:5:1). The resulting oil was dissolved in 100 ml of ether and precipitated by addition of excess anhydrous hydrogen chloride to yield 0.75 g (22% of theory) of 1,3-bis(4-(2-phenyl-2-hydroxyethyl)-1-piperazinyl]propane tetrahydrochloride as a white crystalline product (m.p. 233-240*C).
Example 14 1,3-Bi9-(-4-phenethyl- 1-piperazinyl frpropane dihydrochloride dihydrate A mixture of 5.7 g of 1-phenethylpiperazine, 2.4 g of l-bramo-3-chloropropane, 4.1 g of triethylamine and 30 ml of reagent ethanol was refluxed for 3 hours. 50 ml of water were then added, and the mixture was concentrated to about 40 ml by rotary evaporation. The resulting mixture was extracted with ether (3 x 150 ml), and the extract was evaporated to a brown oil. This oil was dissolved in 150 ml of ether and was precipitated by addition of excess anhydrous hydrogen chloride. The precipitate was dissolved in water and reprecipitated by the addition of acetone to give 3.1 g (37% of theory) of 1,3-bis(4-phenethyl-l-piperazinyl)propane dihydrochloride dihydrate as a white crystalline product (m.p. 210-225aC).
Example 15 1,3-Bis-t4-(4-chlorobenzyl)-1-piperazinyl]-1,3-dioxopropane dihydrochloride monohydrate A mixture of 4.2 g of l-(4-chlorobenzyl)piperazine, 1.4 g of sialonyl dichloride, 10 g of methylene chloridc and -23- 2.0 g of triethylamine was stirred for 60 hours. The reaction mixture was made basic with 2N sodium hydroxide. The organic layer was separated, and the aqueous phase was extracted with three 50 ml portions of ether, followed by three 50 ml portions of methylene chloride. The organic phases were combined and mixed with 100 ml of 2N hydrochloric acid. The aqueous phase was separated and made basic with 2N sodium hydroxide solution. The resulting oil was collected and chromatographed on silica, the eluant being CH^C^/CHgOB/ammnninia hydroxide (200:5:1). The appropriate fractions were combined, evaporated to an oil, dissolved in 100 ml of ether and precipitated with excess anhydrous hydrogen chloride. The precipitate was re-crystallized from reagent ethanol to yield 1.3 g (22% of theory) of 1,3-bis[4-(4—chlorobenzyl)-1-piperazinyl]-1,3-dioxopropane dihydrochloride monohydrate as a very slightly yellow crystalline solid (m.p. 199-206*C).
Example 16 1,3-Bis-{4-(4—chlorophenethyl)-l-piperazinyllpropane A mixture of 6.7 g of l-(4- chlorophenethyl) piperazine, 2.4 g of l-bromo-3-chloropropane, 3.1 g of triethylamine and 20 ml of reagent ethanol was refluxed for 3 hours. The reaction mixture was diluted with 50 ml of water and then concentrated to about 50 ml by rotary evaporation. The resulting mixture was extracted with ether (3 x 150 ml), and the extract was evaporated to give a colorless solid which was recrystallized from heptane to yield 3.3 g (45% of thepry) of l,3-bis[4-(4-chlorophen-ethyl)-l-piperazinyl]propane as a white crystalline product (m.p. 87-88°C). -24- Example 17 1,3-Bia-14- (1-phenylethyl)—1-plperazlnvl ] -propane tetrahydrochloride A mixture of 7.6 g of 1-(1-phenylethyl)piperazine, 3.2 g of l-bromo-3-chloropropane and 50 ml of reagent ethanol was refluxed for 5 hours. The solvent was then removed under vacuum, 75 ml of water were added, and the mixture was extracted with ether (3 x 150 ml).jThe ether extract was evaporated to an oil and chromatographed on silica, the eluant being CHjC^/C^OH/ammonium hydroxide (45:5:1). The resulting yellow oil was dissolved in 150 ml of ether and precipitated with excess anhydrous hydrogen chloride to yield 6.1 g (514 of theory) of l,3-bis[4-(l-phenylethyl) -1-piperazinyl]propane tetrahydrochloride. The product was recrystalllzed from ethanol/water to yield a white crystalline solid (m.p. 236-246°C, with decomp.).
Example 18 1,3-Bis [ 4- (4—chlorobenzy 1) -2,5-dime-thy 1-1-piperazinyl]-propane tetrahydrochloride dihydrate (a) A solution of 16 g of p-chlorobenzy1 chloride in 75 ml of reagent ethanol was added dropwise to a solution of 25 g of 2,5-dimethylpiperazine in 75 ml of reagent ethanol. The mixture was stirred overnight and then filtered. The solvent was removed from the filtrate by vacuum. The residue was extracted with ether (3 x 350 ml), and the extract was evaporated to an oil and chromatographed on silica, the eluant being CHjClj/CH^OH/amraonium hydroxide (45:5:1). This yielded 9.1 g (38* of theory) of 1-(4-chlorobenzyl)-2,5- -25- dimethylpiperazine as a colorless liquid which was used in the following step. (b) A mixture of 6.0 g of 1-(4-chlorobenzyl)-2,5-dimethyl-piperazine, 2.0 g of l-bromo-3-chloropropane, 3.2 g of triethylamine and SO ml of reagent ethanol was refluxed for 6 hours. The solvent was then removed under vacuum, 50 ml of water were added, and the mixture was extracted with ether (3 x 150 ml). The extract was then evaporated to an oil and chromato-graphed on silica, the eluant being CHjCIj/CHjOH/ ammonium hydroxide (45:5:1). The product was dissolved in 150 ml of ether and precipitated with excess anhydrous hydrogen chloride. The precipitate was dissolved in water and reprecipitated by addition of acetone to give 0.7 g of 1,3-bis[4-(4-chlorobenzyl)-2,5-dimethy1-1-piperazinyl]propane tetrahydrochloride dihydrate as a white crystalline product (m.p. 204-214°C).
Example 19 1.3-Bis-[4-(4-methoxybenzvl)-1-piperazlnyl1propane A mixture of 4.1 g of 1-(p-methoxybenzyl)piperazine, 1.6 g of l-bromo-3-chloropropane, 25 ml of reagent ethanol and 2.5 ml of triethylamine was refluxed for 5 hours. The resul'ting mixture was evaporated under vacuum, and the residue was mixed with 25 ml of water and extracted with ether. The extract was evaporated to a yellow oil which solidified on standing. Recrystallization twice from heptane resulted in 2.3 g (51* of theory) of 1,3-bis[4-(4-methoxy-benzyl) -1-piperazinyl] propane as a white crystalline solid (m.p. 86-87"C). -26- Example 20 1,3-Bis-[4-(3,4—dichlorobenzyl)-1-pjperazinyl]-propane tetrahydrochloride A mixture of 5.2 g of 1-(3,4-dichlorobenzyl)-piperazine, 2.2 g of l-bromo-3-chloropropane, 3.0 g of triethylamine and 20 g of reagent ethanol was refluxed.
After 1 hour an additional 0.06 g of l-bromo-3-cbloro-propane was added, and after another hour another 0.06 g of the dihalide was added. The mixture was refluxed overnight and then evaporated under vacuum to yield a gummy solid which was mixed with 150 ml of ether and filtered. The filtrate was dried over magnesium sulfate. Hydrogen chloride-saturated ether was added to the filtrate until the mixture remained acidic when tested with litmus. The resulting precipitate was dissolved in a minimum amount of water. Concentrated hydrochloric acid was then added dropwise, forming a heavy precipitate. Addition was continued until no further precipitation occurred. Filtration and drying under vacuum resulted in 4,5 g (44% of theory) of 1,3-bis[4-(3,4—dichlorobenzyl)-1-piperazinyl]propane tetrahydrochloride as white needles (m.p. 245-251®C, with decomp.).
Example 21 1,3-Bis[4-(2—chlorobenzyl)-l-piperazinyl)propane tetrahydrochloride A mixture of 8.4 g of 1—(2-chlorobenzyl)piperazine, 3.2 g of l-bromo-3-chloropropane, 4.0 g of triethylamine and 30 g of reagent ethanol was refluxed overnight. The solvent was evaporated under vacuum, and the residue was -27- mixed with 150 ml of ether and filtered. The filtrate was dried over magnesium sulfate. Hydrogen chloride-saturated ether was then slowly added to the dry filtrate until the resulting mixture tested acidic to litmus. The resulting precipitate was filtered off, dried and weighed. This yielded. 6.1 g (50% of theory) of crude l,3-bis[4-(2-chlorobenzyl)-1-piperazinyl]propane tetrahydrochloride. Recrystallization from ethanol/water yielded a white crystalline solid (m.p. 251-255°C).
Example 22 1.3-Bis-I4- (4—methylbenzyl) -1-piperazinyl I - propane tetrahydrochloride A mixture of 5.7 g of l-(4-methylbenzyl)piperazine, 2.4 g of l-bramo-3-chloropropane, 25 ml of reagent ethanol and 3.0 g of triethylamine was refluxed for 5 hours. The solvent was removed under vacuum, and the residue was mixed with 40 ml of water. The resulting aqueous mixture was extracted with ether (3 x 150 ml). Evaporation of the ether resulted in a light yellow oil which solidified on standing. This product was dissolved in 50 ml of ether, and hydrogen chloride-saturated ether was added until the mixture tested acidic to litmus. The resulting precipitate was dissolved in 20 ml of water, and acetone was added until product ceased coining out of solution. This yielded 5.8 g (68% of theory) of l,3-bis[4-(4—methylbenzyl)-l-piperazinyl]propane tetrahydrochloride as a white crystalline product (m.p. 245-252*C, with decomp.). 28- Example 23 1,3-Bis(4-(3-ehlorobenzy1)-1-piperazinyl]-propane dihydrochloride -monohydrate A mixture of 6.3 g of l-(3-chlorob«nzyl)piperazine, 2.4 g of l-bromo-3-chloropropane, 50 ml of reagent ethanol and 3.0 g of triethylamine was refluxed for 4 hours. Water (70 ml) was added, and the mixture was concentrated under vacuum to about 70 ml. The resulting aqueous mixture was extracted with ether (3 x 150 ml), and the extract was concentrated under vacuum to give a reddish-yellow oil. Chromatography of this oil on a silica column, the eluant being CHjClj/CH^H/anmonium hydroxide (45:5:1), resulted in an oil which was dissolved in 50 ml of ethanol. Hydrogen chloride-saturated ether was added to this solution until the mixture tested acidic to litmus. The resulting precipitate was filtered off, dried and weighed to yield 5.6 g (68% of theory) of l,3-bis[4-(3-chlorobenzyl)-l-piperazinyl] propane dihydrochloride monohydrate. Recrystallization from water gave a white crystalline solid (m.p. 248-257°C, with decomp.).
Example 24 1,3-Bis 14-(3-{4-chloropheny1)propyl)-1-piperazinyl] -propane tetrahydrochloride monohydrate (a) A mixture of 40.6 g of 3-(4-chlorophenyl)propyl chloride, 130.0 g of anhydrous piperazine and 550 ml of reagent ethanol was refluxed for 2 hours. Solvent was removed under vacuum and the residue was chromatographed on silica with the eluant being CHjCl^j/CHjOH/ammonium hydroxide (45:5:1). Appropriate -29- fractions were combined, concentrated to an oil, mixed with 1400 ml IN HC1 and filtered. The filtrate was brought to pH 10 with concentrated aqueous NaOH and then extracted with ether (4 x 200 ml). The extract was dried over MgSO^ and stripped to an oil which solidified on standing. The resulting 1-13— C4— chlorophenyl)propyl]piperazine (m.p. 54-62°C) was used without further purification A mixture of 7.2 g of 1-[3-(4-chloropheny1)propyl] piperazine, 2.4 g of l-bromo-3-chloropropane, 3.5 g of triethylamine and 30 ml of reagent ethanol was refluxed for 6 hours. The solvent was then evaporated under vacuum, and the residue was mixed with 40 ml of water and extracted with ether (3 x 150 ml). The extract was then evaporated to a yellow oil which was chromatographed on a silica column, the eluant being CHjC^/CH-jOH/annDonium hydroxide (45:5:1). This resulted in 4.6 g (59% of theory) of l,3-bisl4-(3-{4-chloro-phenyl>propyl)-1-piperazinyl]propane as a colorless oil. Part of this oil (3.0 g) was dissolved in 100 ml of ether, and hydrogen chloride-saturated ether was added to this solution until the resulting mixture tested acidic to litmus. The resulting precipitate was dissolved in 25 ml of water, and acetone was added until precipitation appeared complete. This resulted in 2.7 g (41% of theory) of l,3-bisl4-(3-{4-chloro-phenyl>propyl)-1-piperazinyl]propane tetrahydrochloride monohydrate as a white crystalline solid (m.p. 245-246°C, with decomp.). -30- * Example 25 1,3-Bis-[4-t4-chloro-3-trifluororeethylbenzyl)-1-plperazinyl^propane -tetrahydrochloride A. mixture of 11.5 g of 3-chloro-4-trifluoromethyl-5 benzyl chloride, 5.3 g of 1,3-bis(1-piperazinyl)propane, SO g of reagent ethanol and 7.0 g of triethylamine was refluxed for 16 hours. The reaction mixture was evaporated : under reduced pressure, and the residue was mixed with 150 ml of water. The resulting mixture was extracted with 10 ether (5 x 100 ml). The combined extracts were washed with 1M sodium carbonate solution (3 x 100 ml). The resulting ether solution was dried over magnesium sulfate, filtered and evaporated to a yellow oil (6.8 g). This oil was dissolved in 100 ml of hexane and filtered. The filtrate 15 was extracted three times with 20 ml of aqueous 2% acetic acid each. The product was found by TLC to be localized in the second and third extracts. These were combined, made strongly basic with 2N NaOH and extracted with 100 ml ether/hexane (1:1). The extract was dried over anhydrous 20 potassium carbonate and then evaporated. The residual oil (2.6 g) in 10 ml of methanol, upon treatment with 30 ml of hydrogen chloride saturated ether, yielded a white precipitate. An additional 50 ml of ether wets added and the precipitate was filtered off and recrystalllzed from 25 methanol to yield colorless crystalline 1,^-bis[4-(4-chloro-3-trifluoromethylbenzyl)-1-piperazinyl]propane tetrahydrochloride (m.p. 265-268°C, with decomp. >250°C). 30 -31- Example 26 1.3-Bis-{4- H-hydroxybenzyl) -1-piperazinyl Vpropane A mixture of 4.5 g of 1,3-bis[4-(4-methoxybenzylj-l-piperazinyl]propane from Example 19 and 125 ml of 49% hydro-bromlc acid was refluxed for 2 hours end was then cooled and diluted with 125 ml of water. After filtration the aqueous solution was neutralized with 2N sodium hydroxide to adjust the pH to 8. The resulting mixture was extracted three times each with 150 ml of ethanol. The alcohol was then removed by rotary evaporation and the residue was chromatographed on silica with the eluant being methylene chloride containing 1% ammonium hydroxide and 10% methanol to obtain 1.3 g {31% of theory) of 1,3-bis[4-(4-hydroxy-banzyl )-1-piperazinyl]propane as a white crystalline product) melting at 197-201"C.
Example 27 1,3-Bis-[ 4-(4-bromobensyl)-1-piperazinyl(propane tetrahydrochloride A mixture of 3.8 g of l-(4-bromobenzyl)piperazine, 7 g of ethanol, 1.2 g of l-bromo-3-chloropropane and 1.6 g of triethylamine was refluxed for 18 hours. The solvent was then removed by rotary evaporation and the residue was mixed with 50 ml of water and sufficient 2N sodium hydroxide to bring the pH above 10. The resulting mixture was extracted twice with ether (75 + 25 ml) and the combined extract was then washed twice with 25 ml of water, dried over MgSOj and filtered. To this solution was then added HCl-saturated ether until the mixture remained acidic and the resulting precipitate was filtered off and was mixed with 100 ml of 10 15 i 20 25 ethanol. The mixture was brought to reflux and water was added dropwise to the refluxing mixture until a solution was formed. Cooling resulted in the crystallization of the product and filtration yielded 4.2 g (811 of theory) of 1,3-bis[4-(4-bromobenzyl)-1-piperazinyl]propane tetrahydrochloride as- a white crystalline product melting at 237-243°C.
Example 28 1.3-Bis-I4-(4-chlorobenzyl)-l-homopiperazinyl).propana - tetrahydrochloride A mixture of 4.5 g of 1-(4-chlorobenzyl)homopiper-azine, 1.6 g of l-bromo-3-chloropropane and 20 g of ethanol was refluxed for 18 hours. The solvent was removed under vacuum and the mixture was extracted three times with ether (75 ml each) and the extract was evaporated to an oil. This oil was chromatographed on a silica column with the eluant buing methylene chloride containing 0.5% concentrated ammonia hydroxide and 2.5% methanol. The fractions containing the product were combined, evaporated to an oil, dissolved in ether and filtered. The resulting ether solution was mixed with hydrogen chloride-saturated ether until the mixture tested acidic to litmus. The resulting precipitate was dried to obtain 1.4 g- (22% of theory) of product which after crystallization from aqueous ethanol resulted in 1,3-bis[4-(4-chlorobenzyl)-l-homopiperazinyl] propane tetrahydrochloride as a white crystalline product, melting at 218-224"C (decomp.). -33- Example 29 1.3-Bis-[4-(4—f4-chlorophenyl]butyl)-1-piperazinyl1-propane tetrahydrochloride (a) A mixture of 26.4 g of 4-(4-chlorophenyl)butyl chloride, 86.1 g of anhydrous piperazine and 250 ml of reagent ethanol was refluxed overnight. Solvent was evaporated from the product and the residue was chromatograpbed twice on silica with the eluant being CHjClj/CHjOH/aimnonium hydroxide (45:5:1). The first chromatography removed the bulk of the excess piperazine, the second provided 15.2 g of 1-[4-(4-chlorophenyl)butyl]piperazine as a colorless oil which solidified on standing (m.p. 139-145aC). (b) A mixture of 1.5 g of 1-[4-(4-chlorpphenyl)butyl] piperazine, 0.5 g of l-bromo-3-chloropropane, 0.7 g of triethylamine and 10 g of reagent ethanol was refluxed overnight. After addition of 3.5 ml of 2N NaOH, solvent was removed under vacuum. The residue was extracted with methylene chloride and the extract was chromatograpbed on silica with the eluant being CHjClj/CHjOH/ammonium hydroxide (90:10:1). The product fractions were concentrated to an oil and dissolved in ether. HCl-saturated ether was added precipitating 0.7 g (31%) of 1,3-bis[4-(4-{4-chlorophenyl Jbutyl) -1-piperazinyl) propane tetrahydrochloride as a light tan solid. Recrystallization from ethanol/water gave a white crystalline solid (m.p. 213-217°C decomp.). -34- Example 30 1.3-Bis-H-(4-acetoxybenzyl)-l-plperazinyl(propane A mixture of 2.0 g of 1,3-bis14-(4-hydroxybenzyl)-1-piperaziny11propane (Example 26), 1.0 g of pyridine and SO g of acetic anhydride was stirred overnight At ambient temperature. The product mixture was concentrated under vacuum to an amber oil which was mixed with 100 ml of pH 8 phosphate buffer and extracted with ether (3 x 100 ml). The extract was dried over MgS04 and stripped to a white solid. Recrystallization from heptane yielded 1.9 g (78*) of l,3-bis[4-(4-acetoxybenzyl)-l-piperazinyl]propane as a white crystalline solid m.p. 102-105*C.
Example 31 1,3-Bis-{4-(4-butoxybenzyl)-1-piperazinyl(propane -tetrahydrochloride A mixture of 1.0 g of 1,3-bis[4-(4-hydroxybenzyl)-1-piperazinyl]propane (from.example 26), 10 ml of 2N NaOH, 0.2 g of tetrabutylammonium hydroxide (40* in water) and 5.0 g of 1-brombbutane was heated on a steam bath for 3 hours. The mixture was then extracted with ether (3 x 75 ml), dried over MgS04 and evaporated to a colorless oil which solidified on standing. This product was dissolved in 100 ml of ether and HCl-saturated ether was added until precipitation was complete'. Filtration resulted in 1.4 g (91* of theory) of 1,3-bis(4-(4-butoxybenzyl) -1-piperazinyl] propane tetrahydrochloride as a white solid. Recrystallization from reagent ethanol/water resulted in a white crystalline product (m.p. 207-218*0.
Example 32 1.3-Bls-(4-(4-chlorobcnzyl-2,3,5,6-tatramethy1-1-piperaz iny 1 1propane tetrahydrochloride A mixture of l-(4-chlorobenzylJ-2,3,5,6-tetramethyl piperazine, 1 g of 1-bromo-3-chloropropane, and 1 g of triethylamine is heated under reflux in 20 ml of ethanol for 24 hours and the reaction mixture is evaporated under reduced pressure to an oil. The residue is dissolved in water and extracted with ether. The ether extract is washed with water and dried over magnesium sulfate. The product is precipitated from the ether solution by precipitation with excess ethereal hydrogen chloride and crystallization from ethanol to provide 1,3-bis[4-(4-chlorobenzyl)-2,3,5,6-tetramethyl-1-piperazinyl]propane tetrahydrochloride as a white crystalline solid.
Example 33 1-[4-(4-chlorobenzyl)-1-piperazinyl]-3-[4-(2-carboxy- 2-phenylethyl)-1-piperazinyl]propane tetrahydrochloride A suspension of 340 mg of 1-[4-(4-chlorobenzyl)-1- piperazinyl]-3-[4-(2-ethoxycarbonyl-2-phenylethyl)-1-piperazinyl)propane tetrahydrochloride in 10 ml of ethanol was treated with 1 ml of aqueous 5M sodium hydroxide and heated under reflux for 1 hour. The reaction mixture was evaporated to dryness under reduced pressure. The residue was mixed with IN hydrochloric acid (3 ml) and the resulting mixture extracted with ether (2 x 10 ml). The extract was discarded and the pH of aqueous phase adjusted to 5.5 with IN hydrochloric acid. Aqueous saturated sodium chloride solution (10 ml) was added and the mixture extracted with -36- butanol (2 x 10 ml). The butanol extract was filtered and treated with excess ethereal hydrogen chloride. The white precipitate was collected and recrystalllzed from aqueous ethanol to yield It-[4-(4-chlorobenzyl)-1-piperazinyl]-3-[4-(2-carboxy-2-phenylethyl)-1-piperazinyl]propane tetrahydrochloride (140 mg, 40% yield) as a white crystalline solid (m.p. 230-245*C decomp.).
Example 34 1,3-BiaK 4-(3-{4-chlorophenyl}propy11-1-hamo-plperazinyl]propane tetrahydrochloride A mixture of 3.8 g of l-(3-(4-chlorophenyl)propyll homapiperazine, 1.2 g of 1-bramo-3-chloropropane, 1.8 g of triethylamine is heated under reflux in 10 ml of ethanol for 18 hours and the reaction mixture evaporated to dryness under reduced pressure. The residue is mixed with water and extracted with ether. The ether extract is evaporated and the residue chromatographed on silica gel [CH2Cl2/CH3OH/NH4OH (35:5:1)]. The resulting oil is dissolved in ether and the product precipitated with excess ethereal hydrogen chloride. Crystallization from ethanol provides 1,3-bis[ 4-(3-{4-chlorophenyl}propyl)-l-homopiperazinyl]propane tetrahydrochloride as a crystalline solid. -37- Example 35 1,3-Bls-{4-(4-chlorobenzyl)-l-homopiperazinyl1-1,3-dioxopropane dihydrochloride 0.7 g of malonyl dichloride is added at once to a solution of 2.2 g of 1-(4-chlorobenzyDhamopiperazine and 1 g of triethylamine in 10 ml of methylene chloride at room temperature and the reaction mixture heated under reflux for one hour and then evaporated under reduced . pressure. The residue is triturated with water and the crude product extracted with methylene chloride and purified by chromatography on silica [CHjC^/Cl^OB/HH2OH (200:5:1)}. The appropriate fractions are evaporated, dissolved in ether and treated with excess ethereal hydrogen chloride to obtain 1,3-bis[4-(4-chlorobenzyl)-1-homopiperazinyl]-1,3-dioxopropane dihydrochloride as a crystalline solid. -38- As mentioned above, mediator release from maat cells and basophils has been Implicated in many allergic and inflammatory disorders. The activity of compounds in inhibiting the noncytotoxic S exocytosis of such mediators can be evaluated in in vitro models such as the inhibition of mediator release from isolated cellular systems induced by antigen-antibody interaction. The following table shows data obtained in examples of such models 10 to illustrate the biological activity of the compounds of the present invention and the broad scope of their effect.
The cellular systems cited therein are as follows: 15 KPMC: Rat peritoneal mast cell preparation; GPBL: Guinea pig basophil-enriched leukocytes; HBL: Human basophil-enriched leukocytes.
A comparison with the activities of the clinical standards, theophylline and disodium cromoglycate (SSCG) 20 in these systems is also provided. -39- Compound of Example Mediator Release Inhibition IC50(jjm)* RPMC GPBIi HBL 1 3 40 2 2 80 20 3 15 10 50 3 16 NT 10 0.7 24 0.5 9 0.7 Theophylline >1000 200 400 DSCG - - >1000 * Concentration of the compound required in the cellular reaction mixture to inhibit 50% of the release of the pharmacological mediators from the target cells. NT = not tested. - 40- Compounds of the present invention, that is compounds of formula I above and non-toxic, 15 pharmacologically acceptable acid addition salts thereof, have been found to exhibit useful pharmacodynamic properties. More particularly, by virtue of their potent inhibition of mediator release in numerous cell systems they exhibit anti-inflammatory and 20 anti-allergic activities in warm-blooded animals such as rats, and may therefore be useful for the treatment of allergic diseases such as allergic asthma, rhinitis, conjunctivitis, hay fever, urticaria, food allergies and the like. Mediator release 25 from mast cells and basophils has been implicated in many allergic and inflammatory disorders.
For pharmaceutical purposes the compounds according to the present invention may be administered to warm-blooded animals topically, perorally, parent-30 erally, rectally or by the respiratory route as active ingredients in customary pharmaceutical compositions, that is, compositions comprising an inert pharmaceutical carrier or excipient and an effective amount of the active ingredient. -41- Compounds of formula I (and salts thereof) which are active when given by the oral route, 5 may be formulated in the form of syrups, tablets, capsules, pills and the like. Preferably, the compositions ace in unit dosage form, or in a form in which the patient can administer to himself a single dose. When the composition is in the 10 form of a tablet, powder or lozenge, any pharmaceutical carrier suitable for formulating solid compositions may be used. Examples of such carriers are various starches, lactose, glucose, sucrose, cellulose, dicalcium phosphate, and chalk. The composition IS may also be in the form of an ingestible capsule (for example of gelatin) containing the compound; or in the form of a syrup, a liquid solution or a suspension. Suitable liquid pharmaceutical carriers include ethyl alcohol, glycerin, saline, water, 20 propylene glycol or sorbitol solution, which may be compounded with flavoring or coloring agents to form syrups.
The compounds of this invention may also be adminis tered by other than the oral route. In accordance with 25 routine pharmaceutical procedure, the compositions nay be formulated, for example, for rectal administration as' a. suppository or for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsior in a pharmaceutical^ acceptable liquid, such as sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids, which may contain bacteriostatic agents, antioxidants, preservatives, buffers, or other solutes to render the solution isotonic with the blood, thickening agents, suspending agents.or other pharmaceutically acceptable additives. Such forms may be presented in unit dose forms such as ampules or disposable injection devices or in multi-dose vials such as a bottle from which the appropriate dose may be withdrawn, or in solid form or concentrate which can be used to prepare an injectable formulation.
Compounds of this invention may also be suitably presented for administration to the respiratory tract as an aerosol or solution for a nebulizer, or as a micro fine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a cue the'particles of active compounds suitably have diameters of less than 20 microns, preferably less than 10 microns.' Where appropriate, small amounts of other anti-allergics, anti-asthmatics and bronchodilators, for example, sympathomimetic amines such as isoprenaline, isoetharine, metaproterenol, salbutamol, phenylephrine, fenoterol and ephedrine; xanthine derivatives such as theophylline and aainophylline; corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.
Compounds of this invention may also be presented as an ointment, cream, lotion, gel, aerosol or solution for topical application to the skin, nose, or eye. Topical solutions for the nose and the eye may contain, in addition to the compounds of this invention, suitable buffers, -43- toxicity adjusters, microbial preservatives, antioxidants and viscosity-impairing agents in an aqueous vehicle. Examples of agents used to increase viscosity are polyvinyl alcohol, cellulose derivatives, polyvinylpyrrolidone, polysorbates or glycerin. Microbial preservatives added may include benzalkonium chloride, thimexosal,' chloro-butanol or phenylethyl alcohol. Topical preparations for the eye may also be presented as ointments in a suitable inert base consisting of mineral oil, petrolatum, polyethylene glycols or lanolin derivatives, along with microbial preservatives.
In any of the foregoing formulations, a suitable dosage unit may contain from 0.005 to 500 mg of active ingredient. The effective dose of compounds of this invention depends on the particular compound employed, the condition of the patient and on the frequency and route of administration, but in general it is in the range of from 0.0001 mg/kg to 10 mg/kg body weight.
As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned, in this case as an anti-allergic agent for the prophylaxis and treatment of for example, asthma, hay-fever, rhinitis or allergic eczema For the preparation of pharmaceutical compositions, the compounds of formula I or salts thereof ace mixed in the usual way with appropriate pharmaceutical carrier substances and aroma, flavoring and coloring matecials and formed, for example, into tablets or capsules or, with the addition of appropriate adjuvants, suspended or dissolved in water or in an oil, for example cocn oil. -44- .
The compounds of this invention can be administered. orally and parenterally in liquid or solid £orm. As injection medium, it is preferred to use water which contains the stabilizing agents, solubilizing agents and/dr buffers conventionally used for injection solutions. Additives 5 of this type include, for example, tartrate, citrate and acetate buffers, ethanol, propylene glycol, polyethylene glycol, complex formers (such as EDTA), antioxidants (such as sodium bisulfite, sodium metabisulfite or ascorbic acid), high-molecular-weight polymers (such as liquid 10 polyethylene oxides) for viscosity regulation, and polyethylene derivatives of sorbitol anhydrides.
Preservatives may also be added, if necessary, such as benzoic acid, methyl or propyl paraben, benzalkonium chloride or other quaternary ammonium compounds. 15 Solid carrier materials which can be used include, for example, starch, lactose, mannitol, methyl cellulose, microcrystalline cellulose, talcum, silica, dicalcium phosphate, and high-molecular-weight polymers (such as polyethylene glycol). 20 Compositions suitable for oral administration can, if desired, contain flavoring and/or sweetening agents. For topical administration, the compounds'of the present invention can also be used in the form of solutions, i powders, or ointments, for which purpose they are mixed 25 with, for example, physiologically compatible diluents or conventional ointment bases. -45- The following examples illustrate a few phar-macuetical dosage unit compositions comprising a compound of the present invention as an active ingredient. The parts are parts by weight unless 5 otherwise specified. 7 -46- Example 36 Tablets The tablet composition is compounded from the following ingredients: 1,3-Bis[4-(4-chlorobenzyl)-1-piperazinyl]propane tetrahydrochloride 0.010 parts Stearic acid 0.010 " Dextrose 1.890 " Total 1.910 parts Preparation: The ingredients are admixed in conventional manner, and the mixture is compressed into 1.91 gin-tablets, each of which is an oral dosage unit composition containing 10 mg of the active ingredient.
Example 37 Ointment The ointment composition is compounded from the following ingredients: 1,3-Bis[4-(4-chlorobenzyl)-1- piperazinyl]-2-hydroxypropane 2.000 parts Fuming hydrochloric acid 0.011 " Sodium pyrosulfite 0.050 " Mixture (1:1) of cetyl alcohol and stearyl alcohol 20.000 " White Vaseline 5.000 " Synthetic bergamot oil 0.07S " Distilled water g.s.ad 100.000 " -47- preparation: The ingredients are uniformly blended in conventional manner into an ointment, 100 mg of which contain 2.0 mg of the active ingredient.
Example 38 Inhalation aerosol The aerosol composition is compounded from the following ingredients: 1,3-Bis[4-(4-chlorobenzyl}-1-piperazinyl]-1,3-dioxopropane dihydrochloride monohydrate 1.00 parts Soybean lecithin 0.20 " Propellant gas mixture (Freon 11, 12 and 14) g.s.ad 100.00 " Preparation: The ingredients are compounded in conventional manner, and the composition is filled into aerosol containers with a metering valve which releases 0.5 to 2.0 mg of active ingredient per actuation of the valve.
Example 39 Hypodermic solution The solution is compounded from the following ingredients: 1,3-Bis[4-(4-chlorophenethy1)-1-piperazinyl]propane dihydrochloride 5.0 parts Sodium pyrosulfite 1.0 * Sodium salt of EDTA 0.5 " Sodium chloride 8.5 " Double-distilled water q.s.ad 1000.0 " -48- Preparation: The individual ingredients are dissolved in a sufficient amount of double-distilled water, the solution is diluted to the indicated concentration with additional double-distilled water, the resulting solution is filtered until free from suspended particles, and the filtrate is filled under aseptic conditions into 1 mi-ampules which are subsequently sterilized and sealed. Each ampule contains 5 mg of the active ingredient.
Example 40 Topical solution (ophthalmic or nasal) The solution composition is compounded from the following ingredients: 1,3-Bis[4-(4-chlorobenzyl)-1-piperaziny1]-2-hydroxypropane tetrahydrochloride Disodium hydrogen phosphate Dihydrogen sodium phosphate Sodium chloride Polyvinyl alcohol Benzalkonium chloride Distilled water g.s.ad Preparation: ■ The ingredients are dissolved in the conventional manner to form an aqueous solution. The solution is appropriately filtered, with the ophthalmic solution requiring sterile filtration. Each ml of the solution contains 0.2 mg of the active ingredient. 0.020 parts 0.75B ■ 0.184 0.365 " 3.500 0.010 100.000 " -49- Any one of the other compounds embraced by formula X or a non-toxic, pharmacologically acceptable acid addition salt thereof may be substituted for the particular active ingredient in Examples 36 ±o 40. Likewise, the amount of active ingredient in these illustrative examples may be varied to achieve the dosage unit range set forth above, and the amounts and nature of the inert pharmaceutical carrier ingredient may be varied to meet particular require- -50-

Claims (18)

1. Bis-(p1perazinyl- or homoplperazinyl) alkanes of the general 5 formula I (XI wherein Rl* r2' r3 and R4 wh*ch be identical to or different 15 from each other, are each hydrogen, alkyl having 1 to 4 carbon atoms, hydroxyl, alkoxy having 1 to 4 carbon atoms, alkanoyloxy having up to 4 carbon atoms, halogen, trlhalomethyl, d1-Cl_^ alkylanino, alkoxycarbonyl, nltro, cyano or acyl having 1 to 3 carbon atoms; Rg and Rg, which may be identical to or different from each 20 other, are each hydrogen, methyl, hydroxyl, carboxyl, C^_4 alkoxycarbonyl, hydroxymethyl, phenyl or p-chlorophenyl; Rj and Rg are each hydrogen or methyl; j and k are Integers from 0 to 3, their sum being no more than 4; m and n are integers from 0 to 3, their sum being no more than 4; 25 A is -CH2- or -CHgCHg-; or Rg and Ry together or Rfi and Rg together are oxo, provided k or m is other than 0; or Rg and Ry together and Rg and Rg together are oxo, provided k or m Is other than 0; 30 Rg and R^g, which may be the same or different, represent hydrogen or from one to four methyl substituents on the carbon atoms of the piperazine ring (A ■ -CH2-); RU'R12' R13 and R14* whictl ^ identical to or different from each other, are each hydrogen or methyl; or 35 Rjj and R^ together and/or R13 arid RJ4 together are oxo; and -51- X is alkylene of 1 to 2 carbon atoms, optionally hydroxy-substituted with the proviso that when A ■ -CHj-, to Rj4 are hydrogen and j, k, ■ and n are each zero, then X cannot be 1,2-ethylenedlol, and physiologically acceptable acid addition salts 5 thereof.
2. A coapound according to claia 1 of foraila II ?7 flT fl3 *s "u "w S 15 wherein j, k, ■ and n are each 0, 1 or 2; R2 and R^ are -H, -CI, -CHj or C14 alkoxy; Rg, Rgi Rg as well as ^13* ^14 ®nd X are as set forth In claln 1, and physiologically acceptable acid 20 addition salts thereof.
3. A coapound according to claia 1 of fornila III ?11 f 15 ?13 CCH2) C b^-c, 12 *14 (III) 30 wherein Rjj and R^ are H, or together are oxo; is H or OH; R13 and R14 are H, or together are oxo; and a and b are each 1, 2, 3 or 4, and phylologically acceptable 35 acid addition salts thereof.
4. l,3-bis[4-(4-chlorobenzyl)-l-piperazinyl] propane and the physiologically acceptable acid addition salts thereof. -52-
5.. l,3-b1s[4-(4-ch1orobenzyl)-l-p1peraz1nyl]-2-hydroxy-propane and the physiologically acceptable acid addition salts thereof.
6. l,3-bis[4-(4-chlorobenzyl)-l-p1peraz1nyl]-l,3-d1oxo-propane and the physiologically acceptable acid addition salts thereof.
7. l,3-bis[4-(4-chlorophenethyl)-l-p1perazinyl]propane and the physiologically acceptable acid addition salts thereof.
8. l,3-b1s[4-(3-[4-chloropheny1]propyyl)-l-p1perazinyl]propane and the physiologically acceptable acid addition salts thereof.
9. A process for the preparation of b1s-(piperazinyl- or honopiperazinyl) alkanes of general fornula I according to claia 1, wherein a) to prepare symmetric compounds of fornula I a compound of general formula IV wherein R^, R12, Rjj, R^4 and X are as defined In claln 1 and Y and Z are reactive groups is reacted with a conpound of formula V X—C—X—c— (IV) A~\ jlfc-N HK (V) wherein R^, Rg, Rg, R^, Rg, j, k and A are as defined in claln 1; b) reacting a compound of formula VI *2» 7* "Q R (VI) -53- wherein Rji "2* "5* "7* "g1 "ll* "12' "l3* "l4' J* k and A are as defined in claim 1 and Y is a reactive group with a compound of formula VII wherein Rj, R^, Rg, Rg, R1Q, n, n and A are as defined in claim 1. c) (to prepare compounds of formula I, which is symmetrical about central group X) reacting a compound of formula VIII /-a F" HN 8—C—X—C—N NH (VIII) W | I w % *« V V wherein Rg, Rjg, R^, R^, Ri3>Ri4« * and A are as defined in claim 1 with a compound of formula IX 1L a, -(ca2) j—c—(CHj)^—* (ix) '2TV< a, 5 wherein Rj, R2, Rj, R^, Y, j and k are as defined in claim I or d) (to prepare compounds of fornula I wherein X is a carbinol moiety) reacting a compound of formula X 1" /°\/u 1 t~~t 1 *12 H RU - 54 - wherein Rh.Rj2i "13 and "14 are as defined in claim 1 and Y has the sane meaning as in fornula IV, with a conpound of formula VII and optionally converting a conpound of fornula I produced by one of the processes a) to d) into a physiologically acceptable acid addition salt thereof in a manner known per se.
10. A pharmaceutical preparation, containing as active ingredient a compound of the general formula Rz_i: 17 * Tu r- j* r3 r9 *12 "l* *10 « in which Rj, R2, Rj and R4 can be the same or different and are hydrogen, an alkyl group containing 1 to 4 carbon atoms, hydroxy, an alkoxy group containing 1 to 4 carbon atoms, an acyloxy group containing 1 to 4 carbon atoms, halogen, trihalonethyl, di-(ci_4alkyl) amino, C^alkoxycarbonyl, nitro, cyano or acyl containing 1 to 3 carbon atoms, Rg and Rg can be the sane or different and are hydrogen, methyl, hydroxy, carboxy, Cj_4alkoxycarbonyl, hydroxymethyl, phenyl or p-chlorophenyl; Ry and Rg are hydrogen or methyl; j and k are integers fron 0 to 3, their sum being no more than 4; m and n are integers from 0 to 3, their sum being not more than 4;
11. A is -CH2- or -CH2CH2-; or Rg and Ry together or Rg and Rg together are oxo, with the proviso that k or m is not zero or Rg and Ry together and Rg and Rg together are oxo provided that k and m are other than 0; Rg and Rjq are the same or different, and are hydrogen, or one or more methyl substituents on thecarbon atoms of a piperazinyl ring (A ■= -CH2-); 55 - Rjl, Rj2> Rj3 and are the sane or different, are hydrogen or Rjj and R]2 together and/or R13 and RJ4 together are oxo and 5 X is an alkyl chain with 1 to 2 carbon atoms optionally substituted by hydroxy, or a physiologically acceptable acid addition salt thereof, in combination with a conventional carrier or excipient. 10 11. A pharmaceutical preparation containing as an active ingredient a compound according to claim 10, in combination with a further pharmacologically active substance and a conventional carrier or excipient. 15
12. A process for the preparation of a pharmaceutical preparation according to claim 10, wherein a compound according to claim 10 and a conventional galenic carrier or excipient are worked into a conventional pharmaceutical form. 20
13. A process for the preparation of a pharmaceutical preparation according to claim 11, wherein a compound according to claim 10 in combination with another pharmacologically active substance,and a conventional carrier or excipient, are worked into a conventional pharmaceutical form. 25
14. The use of a compound according to claim 10, in the production of a pharmaceutical preparation for the treatment of allergic reactions and inflammations in warm-blooded animals. 30
15. A process for the preparation of (bis-plperazinyl- or homopiperazinyl) alkanes of general formula I substantially as hereinbefore described with reference to any of Examples 1 to 35.
16. . Bis-(p1peraziny1- or homopiperazinyl) alkanes of general formula 35 I whenever prepared by a process as claimed in claim 9 or claim 16. -56-
17. A process for the preparation of a pharmaceutical preparation containing as active ingredient a compound of the general formula 1 substantially as hereinbefore described with reference to any of Examples 36 to 40.
18. A pharmaceutical preparation containing as active ingredient a compound of general formula I whenever prepared by a process as claimed in any of claims 12, 13 or 17. 10 Dated this 20th day of March, 1984. 15 (Signed) BY: DUBLIN 6. 20 25 30 35 t -57-
IE682/84A 1983-03-21 1984-03-20 Bis-(piperazinyl or homopiperazinyl)alkanes IE57136B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47700883A 1983-03-21 1983-03-21

Publications (2)

Publication Number Publication Date
IE840682L true IE840682L (en) 1984-09-21
IE57136B1 IE57136B1 (en) 1992-05-06

Family

ID=23894132

Family Applications (1)

Application Number Title Priority Date Filing Date
IE682/84A IE57136B1 (en) 1983-03-21 1984-03-20 Bis-(piperazinyl or homopiperazinyl)alkanes

Country Status (24)

Country Link
EP (1) EP0122488B1 (en)
JP (1) JPS59176265A (en)
KR (1) KR890000487B1 (en)
AT (1) ATE43843T1 (en)
AU (1) AU568122B2 (en)
CA (1) CA1218652A (en)
CS (1) CS254971B2 (en)
DD (1) DD219642A5 (en)
DE (1) DE3478601D1 (en)
DK (1) DK166022C (en)
ES (4) ES530762A0 (en)
FI (1) FI80269C (en)
GR (1) GR81827B (en)
HU (1) HU191599B (en)
IE (1) IE57136B1 (en)
IL (1) IL71291A (en)
NO (1) NO162907C (en)
NZ (1) NZ207554A (en)
PH (1) PH25216A (en)
PL (2) PL252632A1 (en)
PT (1) PT78278B (en)
SU (2) SU1568887A3 (en)
YU (2) YU45598B (en)
ZA (1) ZA842037B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692448A (en) * 1984-11-20 1987-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Bis(arylpiperazinyl)sulfur compounds
JPS645287Y2 (en) * 1984-11-20 1989-02-09
CA2180190A1 (en) * 1995-07-10 1997-01-11 Kazumi Ogata Benzylpiperazine derivatives
JP4388228B2 (en) * 1998-02-19 2009-12-24 興和株式会社 Cyclic amide compound
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
NZ515374A (en) 1999-05-18 2004-09-24 Teijin Ltd Remedies or prophylactics for diseases in association with chemokines
US7576117B1 (en) * 1999-08-04 2009-08-18 Teijin Limited Cyclic amine CCR3 antagonist
EP1373251A2 (en) * 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA675224A (en) * 1963-12-03 Gabler Rudolf Piperazine derivatives
JPS5914032B2 (en) * 1976-04-09 1984-04-02 日本新薬株式会社 Bistrimethoxybenzylpiperazinoalkanes
US4692448A (en) * 1984-11-20 1987-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Bis(arylpiperazinyl)sulfur compounds

Also Published As

Publication number Publication date
ES8505992A1 (en) 1985-06-16
SU1574174A3 (en) 1990-06-23
PT78278B (en) 1986-08-08
CS254971B2 (en) 1988-02-15
PL246774A1 (en) 1985-07-30
DE3478601D1 (en) 1989-07-13
GR81827B (en) 1984-12-12
YU45598B (en) 1992-07-20
EP0122488B1 (en) 1989-06-07
ZA842037B (en) 1985-12-24
ES535439A0 (en) 1985-09-16
ATE43843T1 (en) 1989-06-15
DK160184A (en) 1984-09-22
ES530762A0 (en) 1985-06-16
FI80269C (en) 1990-05-10
AU568122B2 (en) 1987-12-17
YU48284A (en) 1987-10-31
FI80269B (en) 1990-01-31
CA1218652A (en) 1987-03-03
IE57136B1 (en) 1992-05-06
IL71291A0 (en) 1984-06-29
PT78278A (en) 1984-04-01
ES535438A0 (en) 1985-09-16
DK166022C (en) 1993-08-02
FI841081A0 (en) 1984-03-19
FI841081A (en) 1984-09-22
SU1568887A3 (en) 1990-05-30
NZ207554A (en) 1987-03-31
KR890000487B1 (en) 1989-03-18
ES535440A0 (en) 1985-09-16
ES8600230A1 (en) 1985-09-16
CS196084A2 (en) 1987-07-16
DK160184D0 (en) 1984-03-20
HUT34016A (en) 1985-01-28
DD219642A5 (en) 1985-03-13
AU2589184A (en) 1984-09-27
NO841078L (en) 1984-09-24
PH25216A (en) 1991-03-27
NO162907C (en) 1990-03-07
ES8600228A1 (en) 1985-09-16
IL71291A (en) 1987-11-30
JPS59176265A (en) 1984-10-05
EP0122488A1 (en) 1984-10-24
YU107286A (en) 1987-10-31
ES8600229A1 (en) 1985-09-16
PL141127B1 (en) 1987-06-30
DK166022B (en) 1993-03-01
KR840008007A (en) 1984-12-12
HU191599B (en) 1987-03-30
PL252632A1 (en) 1986-01-14
NO162907B (en) 1989-11-27

Similar Documents

Publication Publication Date Title
US3813384A (en) Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
EP0079545B1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
NZ199650A (en) 2-(4-(diphenylmethyl)-1-piperazinyl)-acetic acid derivatives
JPS62111962A (en) 3-phenylthiomethylstyrene derivative
IE840682L (en) Bis(piperazinyl or homopiperazinyl) alkanes
JPH06184155A (en) 4,5-dihydro-4-oxo-pyrrolo(1,2-a)quinoxaline, its aza analogue, their production, medicines containing said compounds and production of said medicines
US3907826A (en) Novel benzo(b)thiophene derivatives and processes for their preparation
JPS6242905B2 (en)
US4725597A (en) Bis(piperazinyl or homopiperazinyl)alkanes
US4065451A (en) 1,3-Dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetate esters and their acid salts
CA1094070A (en) 1-phenyl-piperazine derivatives
FI76794B (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA SPIROTIAZOLIDINDIONDERIVAT.
EP0127182B1 (en) 1-phenylalkyl-4-(mercapto and carbamylthio)alkyl-piperazines and -homopiperazines and their use in the treatment of allergic diseases
US3849438A (en) 2-substituted-3-disubstituted-4,5,6,7-substituted or unsubstituted phthalimidines
US3576809A (en) 2-substituted derivatives of 6-methoxyquinoline
US3553267A (en) 3-dimethylamino-1,2,3,4-tetrahydrofluorene
JPS6391374A (en) Imidazolium hydrogen carbonate
EP0486211A1 (en) Isoquinoline derivatives
US3250777A (en) Bis-arylsulfonylureas
CS254998B2 (en) Method of new bis-(piperazinyl-or homopiperazinyl)alcanes production
CA1215364A (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
NZ197103A (en) 3h-2-benzazepines

Legal Events

Date Code Title Description
MM4A Patent lapsed